Meeting News

Meeting News

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

Infusion with “non-engineered” adoptive T-cell products induced responses in select patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) who had undergone allogeneic...

RADIUS: Midostaurin Reduces Post-Transplant Relapse Risk in FLT3-Mutated AML

Post-transplant maintenance therapy with midostaurin was safe and reduced relapse risk in patients with FLT3-mutated acute myeloid leukemia (AML), according to findings from the...

Prognostic Significance of Post-Transplant MRD Varies Based on Conditioning Regimen in ALL

Assessment of measurable residual disease (MRD) prior to allogeneic hematopoietic cell transplantation (alloHCT) is an established important prognostic factor in patients with acute lymphocytic...

How Do Patient and Physician Attitudes Drive Choices in Antiplatelet Therapy for Thrombocytopenia?

Patients with a hematologic malignancy and thrombocytopenia typically are treated with antiplatelet drugs, but there is little information to help clinicians balance the potential...

CPX-351 Outperforms Induction Chemotherapy in Older High-Risk Patients With AML

Older patients (≥60 years of age) with acute myeloid leukemia (AML) often have lower remission rates and increased induction mortality with intensive induction chemotherapy,...

Durable Response Observed With Pracinostat and Azacitidine for Older Patients With AML

The inhibition of both histone deacetylation (HDAC) and DNA hypermethylation induces re-expression of silenced genes in vitro in cell lines and in primary cells...

More Mutations, More Problems? Assessing Mutation Burden and Response to HMAs in MDS

Previous research has suggested that the presence of a TET2 mutation can predict which patients with myelodysplastic syndromes (MDS) are more likely to have...

SWOG S1203: Comparing Standards of Care for Acute Myeloid Leukemia

Investigators from the phase III US Intergroup SWOG-led S1203 trial reported that remission induction with 7+3 chemotherapy (cytarabine plus daunorubicin) should remain the standard...

Azacitidine and Donor Lymphocyte Infusions Reduce Risk of Relapse in Post-Transplant AML and MDS

Although allogeneic hematopoietic cell transplantation (alloHCT) is currently the only curative option for many patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS),...

Optimizing Post-Transplant Outcomes for Patients With MDS

Two analyses from the European Society for Blood and Marrow Transplantation (EBMT) reported on post-allogeneic hematopoietic cell transplantation (alloHCT) among patients with myelodysplastic syndromes...
Advertisement

Current Issue

May 2019, Volume 5, Issue 6

This issue features a look at home-based care for hematologic disorders, strides in pediatric leukemia in El Salvador, and more.